Literature DB >> 8637789

Rheumatic fever prophylaxis using benzathine penicillin G (BPG): two- week versus four-week regimens: comparison of two brands of BPG.

A S Kassem1, S R Zaher, H Abou Shleib, A G el-Kholy, A A Madkour, E L Kaplan.   

Abstract

OBJECTIVE: This prospective study was aimed at answering two important questions: 1) Is a biweekly schedule of 1.2 million U intramuscular benzathine penicillin G (BPG) superior to a 4-week one in the prevention of upper respiratory Group A beta-hemolytic streptococcal (GABHS) infections and rheumatic fever (RF) recurrences? 2) Is there a difference in the bioavailability of BPG obtained from different manufacturers?
METHODOLOGY: Three hundred sixty rheumatic patients aged 4 to 20 years were randomly assigned to either a biweekly (190 patients) or 4-week (160 patients) BPG prophylactic schedule and were followed-up monthly for 2 years by clinical examination, throat swab culture for GABHS and measurement of antistreptolysin O titer to detect GABHS infection and/or recurrences of RF (according to revised Jones' Criteria). Thereafter, 34 rheumatic subjects, aged 8 to 16 years were randomly assigned to receive a 4-week injection of 1.2 million U of either a locally manufactured BPG brand (22 patients) or an imported one (12 patients). Sera of all patients were tested for penicillin level by plate diffusion method on days 1, 2, 3, 4, 5, 6, 7, 14, 21, and 28 after the intramuscular injection of BPG.
RESULTS: The GABHS infection rate was found to be 0.2% and 0.3% for patients on the biweekly and 4-week BPG schedules, respectively, with no significant differences between them. However, the RF recurrence rate/patient/year for the 4-week schedule patients (0.12) was double that for the biweekly schedule ones (0.06). Estimation of the bioavailability of the two different brands of BPG demonstrated a difference in their pharmacokinetics and a decrease in the serum penicillin concentration below the minimum inhibitory concentration 3 weeks after the injection of either brand.
CONCLUSION: Although a biweekly schedule may not be superior in preventing upper respiratory GABHS infection, it may play a role in preventing the sequelae of such infections. The short duration of penicillinemia explains the superiority of the 2-week schedule in RF prophylais. The difference in the pharmacokinetics of penicillin brands might contribute to the high recurrence rate of RF reported in Egypt.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8637789

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  7 in total

1.  A population pharmacokinetic modeling approach shows that serum penicillin G concentrations are below inhibitory concentrations by two weeks after benzathine penicillin G injection in the majority of young adults.

Authors:  Michael Neely; Edward L Kaplan; Jeffrey L Blumer; Dennis J Faix; Michael P Broderick
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

Review 2.  Penicillin for secondary prevention of rheumatic fever.

Authors:  J Manyemba; B M Mayosi
Journal:  Cochrane Database Syst Rev       Date:  2002

3.  Severe adverse events following benzathine penicillin G injection for rheumatic heart disease prophylaxis: cardiac compromise more likely than anaphylaxis.

Authors:  Shannon Marantelli; Robert Hand; Jonathan Carapetis; Andrea Beaton; Rosemary Wyber
Journal:  Heart Asia       Date:  2019-06-20

4.  Global research priorities in rheumatic fever and rheumatic heart disease.

Authors:  Jonathan R Carapetis; Liesl J Zühlke
Journal:  Ann Pediatr Cardiol       Date:  2011-01

5.  The role of benzathine penicillin G in predicting and preventing all-cause acute respiratory disease in military recruits: 1991-2017.

Authors:  Jacob D Ball; Mattia A Prosperi; Alfonza Brown; Xinguang Chen; Eben Kenah; Yang Yang; Derek A T Cummings; Caitlin M Rivers
Journal:  Epidemiol Infect       Date:  2018-07-05       Impact factor: 4.434

6.  Cardiovascular complications in newly diagnosed rheumatic heart disease patients at Mulago Hospital, Uganda.

Authors:  Emmy Okello; Zhang Wanzhu; Charles Musoke; Aliku Twalib; Barbara Kakande; Peter Lwabi; Nyakoojo B Wilson; Charles K Mondo; R Odoi-Adome; Juergen Freers
Journal:  Cardiovasc J Afr       Date:  2013-04       Impact factor: 1.167

7.  Quality of benzathine penicillin G: A multinational cross-sectional study.

Authors:  Robert M Hand; S M D K Ganga Senarathna; Madhu Page-Sharp; Katherine Gray; Dianne Sika-Paotonu; Meru Sheel; Victor T G Chuang; Jorge Martinez; Giuseppe Luna; Laurens Manning; Rosemary Wyber; Jonathan R Carapetis; Kevin T Batty
Journal:  Pharmacol Res Perspect       Date:  2020-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.